Table 5.

Univariate Analysis with Respect to DFS

	N. Pts	N. Events	% 5-Year DFS (95% CI)	P	HR (95% CI)
Overall	160	13	92 (88–97)	-	-
CD4
Negative	73	7	92 (85–99)		1.00
Positive	70	6	90 (82–99)	.906	1.07 (0.36–3.19)
CD8
Negative	77	7	92 (84–99)		1.00
Positive	74	5	94 (88–100)	.512	0.68 (0.22–2.15)
FOXP3
Negative	65	5	95 (89–100)		1.00
Positive	84	7	91 (83–98)	.793	1.17 (0.37–3.68)
CTLA4
Negative	87	9	90 (83–97)		1.00
Positive	65	3	96 (91–100)	.193	0.43 (0.12–1.59)
PD-1 in TILs
Negative	103	10	91 (85–97)		1.00
Positive	36	3	91 (82–100)	.895	0.92 (0.25–3.33)
PD-L1 in TILs
Negative	115	8	93 (88–99)		1.00
Positive	31	4	88 (74–100)	.228	2.06 (0.62–6.85)
PD-L1 in tumor cells
Negative	141	11	92 (87–97)		1.00
Positive	6	1	100	.534	1.89 (0.24–14.69)
sCD4
Negative	75	7	92 (86–99)		1.00
Positive	68	6	90 (82–99)	.832	1.13 (0.38–3.35)
iCD4
Negative	77	6	92 (86–99)		1.00
Positive	66	7	90 (82–99)	.474	1.49 (0.50–4.42)
sCD8
Negative	76	9	89 (81–97)		1.00
Positive	75	3	97 (92–100)	.064	0.31 (0.08–1.15)
iCD8
Negative	75	3	95 (90–100)		1.00
Positive	76	9	90 (82–98)	.050	3.42 (0.93–12.67)

s = stromal.

i = intratumoral.